TCM
VRTX icon

Twin Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Twin Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$839K Sell
1,879
-40
-2% -$18.7K 0.11% 184
2025
Q4 		$870K Buy
1,919
+14
+0.7% +$6.03K 0.11% 172
2025
Q3 		$746K Buy
+1,905
New +$796K 0.09% 192
2025
Q1 		– Sell
-2,933
Closed -$1.18M – 322
2024
Q4 		$1.18M Sell
2,933
-2,826
-49% -$1.31M 0.13% 154
2024
Q3 		$2.68M Sell
5,759
-135
-2% -$64.8K 0.3% 94
2024
Q2 		$2.76M Buy
5,894
+30
+0.5% +$13K 0.33% 81
2024
Q1 		$2.45M Sell
5,864
-328
-5% -$139K 0.3% 99
2023
Q4 		$2.52M Sell
6,192
-162
-3% -$59.8K 0.33% 92
2023
Q3 		$2.21M Sell
6,354
-441
-6% -$154K 0.32% 93
2023
Q2 		$2.39M Sell
6,795
-262
-4% -$88.3K 0.31% 96
2023
Q1 		$2.22M Sell
7,057
-3,564
-34% -$1.07M 0.3% 103
2022
Q4 		$3.07M Sell
10,621
-33
-0.3% -$10.1K 0.4% 76
2022
Q3 		$3.08M Sell
10,654
-70
-0.7% -$20.1K 0.42% 66
2022
Q2 		$3.02M Buy
10,724
+4,235
+65% +$1.13M 0.39% 80
2022
Q1 		$1.69M Buy
6,489
+85
+1% +$20.2K 0.18% 151
2021
Q4 		$1.41M Buy
6,404
+1,229
+24% +$239K 0.14% 169
2021
Q3 		$939K Buy
+5,175
New +$1.01M 0.1% 203
2019
Q1 		– Sell
-11,770
Closed -$1.95M – 278
2018
Q4 		$1.95M Sell
11,770
-33,450
-74% -$5.8M 0.11% 207
2018
Q3 		$8.72M Buy
45,220
+1,450
+3% +$258K 0.4% 74
2018
Q2 		$7.44M Buy
43,770
+300
+0.7% +$46.5K 0.37% 89
2018
Q1 		$7.08M Buy
43,470
+24,720
+132% +$4.04M 0.37% 90
2017
Q4 		$2.81M Buy
+18,750
New +$2.78M 0.14% 191

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Twin Capital Management's VRTX Position: Q1 2026 in Review

Twin Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2.1% in Q1 2026, selling an estimated $18.7K and leaving 1,879 shares worth $839K. The position accounts for 0.11% of the portfolio, ranked #184.

Twin Capital Management first reported a position in VRTX in Q4 2017 and has held it in 22 quarters since. The position peaked at $8.72M in Q3 2018. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Twin Capital Management held 1,879 shares of Vertex Pharmaceuticals worth $839K as of Q1 2026.
  • Twin Capital Management sold 40 Vertex Pharmaceuticals shares in Q1 2026, an estimated $18.7K.
  • Vertex Pharmaceuticals made up 0.11% of Twin Capital Management's portfolio in Q1 2026, its #184 holding.
  • Twin Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 22 quarters since.
  • Twin Capital Management's Vertex Pharmaceuticals position peaked at $8.72M in Q3 2018.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Twin Capital Management's 13F filing for Q1 2026, filed 5 May 2026.